MedTrace Logo

Pectoral Nerve Block and Serratus Posterior Superior Intercostal Plane Block in Breast Cancer Surgery

NCT07001657 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2026-01-28

No results posted yet for this study

Summary

This randomized clinical trial aims to evaluate and compare the analgesic efficacy of the Pectoral Nerve Block (PECS II) and the Serratus Posterior Superior Intercostal Plane (SPSIP) Block in patients undergoing breast cancer surgery. The primary outcome is total opioid consumption in the first 24 hours. Secondary outcomes include pain scores (VAS), block performance time, number of needle passes, postoperative recovery quality (QoR-15), time to first analgesic request, and complications (hematoma, pneumothorax, local anesthetic toxicity, vascular puncture, infection).

Conditions

  • Nerve Block

Interventions

PROCEDURE

SPSIP Block

Patients in this group will receive an ultrasound-guided Serratus Posterior Superior Intercostal Plane (SPSIP) block with 30 mL of 0.25% bupivacaine hydrochloride injected into the fascial plane between the serratus posterior superior muscle and the third rib, 30 minutes before surgery.

PROCEDURE

PECS II Block

Patients in this group will receive an ultrasound-guided PECS II block with 30 mL of 0.25% bupivacaine hydrochloride (20 mL between the pectoralis minor and serratus anterior muscles, and 10 mL between the pectoralis major and minor muscles), 30 minutes before breast cancer surgery.

Sponsors & Collaborators

  • Antalya Training and Research Hospital

    lead OTHER_GOV

Principal Investigators

  • Nilgun Kavrut Ozturk, professor · Antalya Training and Research Hospital

  • Yunus Emre Songur, Resident · Antalya Training and Research Hospital

  • Bahadır Ciftci, Assoc Prof · Medipol Mega University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-25
Primary Completion
2025-12-01
Completion
2026-01-27

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07001657 on ClinicalTrials.gov